Reuters logo
BRIEF-Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab In X-Linked Hypophosphatemia
December 4, 2017 / 12:43 PM / 10 days ago

BRIEF-Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab In X-Linked Hypophosphatemia

Dec 4 (Reuters) - Ultragenyx Pharmaceutical Inc:

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE POSITIVE 48-WEEK DATA FROM ADULT PHASE 3 STUDY OF BUROSUMAB (KRN23) IN X-LINKED HYPOPHOSPHATEMIA Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below